Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
SANTA CLARA, Calif., Aug. 22, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today the appointment of Dr. Leon Hall as Vice President of Global Scientific Excellence. In his new role, Dr. Hall will be responsible for overseeing global R&D programs and advancing Crown Bioscience’s scientific excellence initiatives.
“Leon’s appointment reinforces Crown Bioscience’s dedication to innovation and commitment to providing the highest quality therapeutic technology services," said Jean-Pierre Wery, Ph.D., Crown Bioscience Chief Executive Officer. "His extensive scientific and operational experience will serve Crown Bioscience well as we expand to meet the growing needs of preclinical research to the global biopharmaceutical market worldwide."
“I am excited about contributing to the expansion of Crown Bioscience’s translational technology platform at a higher level,” said Dr. Hall. “I look forward to continuing Crown Bioscience’s commitment to quality and scientific integrity embedded throughout the global organization.”
Dr. Hall previously served as Crown Bioscience’s Senior Scientific Director and led Crown Bioscience’s Global Scientific Excellence Initiative. Dr. Hall established the Global Quality Council as well as the Global Scientific Councils that govern Crown Bioscience’s research in oncology, immunology, inflammation, cardiovascular and metabolic diseases. His efforts have ensured global standards of excellence, harmonization and fostered collaborations in scientific innovation and R&D.
Leon holds a Ph.D. from the University of Leicester, England, in Molecular Pathology and Toxicology. He has over 15 years of preclinical rodent research experience and is considered an industry leader in the application of humanized mouse models in immunology and immuno-oncology.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. [email protected]
